• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by DA32 Life Science Tech Acquisition Corp. (Amendment)

    5/15/23 5:01:32 PM ET
    $DALS
    Blank Checks
    Finance
    Get the next $DALS alert in real time by email
    SC 13G/A 1 tm2315331d2_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    ______________

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    DA32 Life Science Tech Acquisition Corp.

    (Name of Issuer)

     

    Class A Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    23312M106

    (CUSIP Number)

     

    ___________May 15, 2023__________

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

    x Rule 13d-1(c)

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 23312M106

     




    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Management, L.P.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨ 

    (b)       ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF 5

    SOLE VOTING POWER

     

    0 

    SHARES 

    BENEFICIALLY 

    OWNED BY

    6

    SHARED VOTING POWER

     

    0

    EACH 

    REPORTING 

    PERSON

    7

    SOLE DISPOSITIVE POWER

     

    0

    WITH: 8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA, PN

     

     

     

     

     

    CUSIP No. 23312M106

     




    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Peter Kolchinsky

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨ 

    (b)       ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America 

     

     

     

    NUMBER OF 

    5

    SOLE VOTING POWER

     

    0

     

    SHARES 

    BENEFICIALLY 

    OWNED BY

    6

    SHARED VOTING POWER

     

    0

    EACH 

    REPORTING 

    PERSON

    7

    SOLE DISPOSITIVE POWER

     

    0

    WITH: 8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, IN

     

     

     

     

     

    CUSIP No. 23312M106

     




    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Rajeev Shah

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨ 

    (b)       ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

     

     

     

    NUMBER OF 

    5

    SOLE VOTING POWER

     

    0

     

    SHARES 

    BENEFICIALLY 

    OWNED BY

    6

    SHARED VOTING POWER

     

    0

    EACH 

    REPORTING 

    PERSON

    7

    SOLE DISPOSITIVE POWER

     

    0 

    WITH: 8

    SHARED DISPOSITIVE POWER

     

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, IN

     

     

     

     

     

    CUSIP No. 23312M106

     




    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Healthcare Fund, L.P.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨ 

    (b)       ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     

    NUMBER OF 

    5

    SOLE VOTING POWER

     

    0 

    SHARES 

    BENEFICIALLY 

    OWNED BY

    6

    SHARED VOTING POWER

     

    0

    EACH 

    REPORTING 

    PERSON

    7

    SOLE DISPOSITIVE POWER

     

    0 

    WITH: 8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

     

     

     

     

     

    Item 1(a).Name of Issuer:

     

    DA32 Life Science Tech Acquisition Corp (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    345 Park Avenue South, 12th Floor, New York, New York 10010

     

    Item 2(a).Names of Persons Filing:

     

    The names of the persons filing this report (collectively, the “Reporting Persons”) are: 

    RA Capital Management, L.P. (“RA Capital”) 

    Peter Kolchinsky

    Rajeev Shah  

    RA Capital Healthcare Fund, L.P. (the “Fund”)

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    The address of the principal business office of each of the Reporting Persons is: 

    c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116

     

    Item 2(c).Citizenship:

     

    RA Capital and the Fund are Delaware limited partnerships. Dr. Kolchinsky and Mr. Shah are United States citizens.

     

    Item 2(d).Title of Class of Securities:

     

    Class A Common Stock, par value $0.0001 per share (“Ordinary Shares”)

     

    Item 2(e).CUSIP Number:

     

    23312M106

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

     

     

     

    Item 4.Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)

    Amount Beneficially Owned:

    See the response(s) to Item 9 on the attached cover page(s).

     

    (b)

    Percent of Class:

    See the response(s) to Item 11 on the attached cover page(s).

       
    (c) Number of shares as to which such person has:
       
      (i)

    sole power to vote or to direct the vote:

    See the response(s) to Item 5 on the attached cover page(s).

         
      (ii)

    shared power to vote or to direct the vote

    See the response(s) to Item 6 on the attached cover page(s).

         
      (iii)

    sole power to dispose or to direct the disposition of

    See the response(s) to Item 7 on the attached cover page(s).

         
      (iv)

    shared power to dispose or to direct the disposition of

    See the response(s) to Item 8 on the attached cover page(s).

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    Exhibit List

     

    Exhibit 1: Joint Filing Agreement

     

     

     

     

    SIGNATURE

     

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: May 15, 2023  
         
    RA CAPITAL MANAGEMENT, L.P.  
       
    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Authorized Signatory  
         
    PETER KOLCHINSKY  
       
    /s/ Peter Kolchinsky  
       
    RAJEEV SHAH  
       
    /s/ Rajeev Shah  
       
    RA CAPITAL HEALTHCARE FUND, L.P.  
       
    By: RA Capital Healthcare Fund GP, LLC  
    Its: General Partner  
         
    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Manager  

     

     

     

     

    EXHIBIT 1

     

     

    AGREEMENT

     

    This Joint Filing Agreement, dated as of May 15, 2023, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”).

     

    Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G and/or 13D with respect to Class A Common Stock, par value $0.0001 per share of DA32 Life Science Tech Acquisition Corp. beneficially owned by them from time to time.

     

    Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

     

    This Joint Filing Agreement may be terminated by any of the Filers upon one week’s prior written notice or such lesser period of notice as the Filers may mutually agree.

     

    Executed and delivered as of the date first above written.

     

    RA CAPITAL MANAGEMENT, L.P.  
       
    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Authorized Signatory  
         
    PETER KOLCHINSKY  
       
    /s/ Peter Kolchinsky  
       
    RAJEEV SHAH  
       
    /s/ Rajeev Shah  
       
    RA CAPITAL HEALTHCARE FUND, L.P.  
       
    By: RA Capital Healthcare Fund GP, LLC  
    Its: General Partner  
         
    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Manager  

     

     

     

    Get the next $DALS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DALS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DALS
    SEC Filings

    View All

    SEC Form 15-12G filed by DA32 Life Science Tech Acquisition Corp.

    15-12G - DA32 Life Science Tech Acquisition Corp. (0001863294) (Filer)

    8/7/23 5:56:49 PM ET
    $DALS
    Blank Checks
    Finance

    SEC Form 25-NSE filed by DA32 Life Science Tech Acquisition Corp.

    25-NSE - DA32 Life Science Tech Acquisition Corp. (0001863294) (Subject)

    7/28/23 4:03:35 PM ET
    $DALS
    Blank Checks
    Finance

    DA32 Life Science Tech Acquisition Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - DA32 Life Science Tech Acquisition Corp. (0001863294) (Filer)

    7/21/23 4:19:54 PM ET
    $DALS
    Blank Checks
    Finance

    $DALS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Crandell Keith disposed of 1,600,000 shares

    4 - DA32 Life Science Tech Acquisition Corp. (0001863294) (Issuer)

    8/10/23 8:28:16 PM ET
    $DALS
    Blank Checks
    Finance

    SEC Form 4: Arch Venture Fund Xi, L.P. disposed of 1,600,000 shares

    4 - DA32 Life Science Tech Acquisition Corp. (0001863294) (Issuer)

    8/10/23 8:27:17 PM ET
    $DALS
    Blank Checks
    Finance

    SEC Form 4: Deerfield Management Company, L.P. (Series C) disposed of 1,600,000 shares

    4 - DA32 Life Science Tech Acquisition Corp. (0001863294) (Issuer)

    8/1/23 5:24:40 PM ET
    $DALS
    Blank Checks
    Finance

    $DALS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DA32 Life Science Tech Acquisition Corp. Announces Redemption of Shares

    DA32 Life Science Tech Acquisition Corp. (NASDAQ:DALS) today announced that its board of directors (the "Board") has determined to redeem all of its outstanding shares of Class A common stock (the "Public Shares"), effective as of July 28, 2023, because the Company will not consummate an initial business combination within the time period required by its amended and restated certificate of incorporation. As of the close of business on July 28, 2023, the Public Shares will be deemed cancelled and will represent only the rights to receive the per-share redemption price of approximately $10.31 (after taking into account the removal of a portion of the accrued interest in the trust account to

    7/21/23 4:05:00 PM ET
    $DALS
    Blank Checks
    Finance

    $DALS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by DA32 Life Science Tech Acquisition Corp. (Amendment)

    SC 13G/A - DA32 Life Science Tech Acquisition Corp. (0001863294) (Subject)

    2/7/24 1:45:26 PM ET
    $DALS
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by DA32 Life Science Tech Acquisition Corp. (Amendment)

    SC 13G/A - DA32 Life Science Tech Acquisition Corp. (0001863294) (Subject)

    9/11/23 4:36:54 PM ET
    $DALS
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by DA32 Life Science Tech Acquisition Corp. (Amendment)

    SC 13G/A - DA32 Life Science Tech Acquisition Corp. (0001863294) (Subject)

    8/8/23 10:29:56 AM ET
    $DALS
    Blank Checks
    Finance